Britain's £15 Million Bet on Brain Technology That Could Treat Depression and Dementia

The UK government has just given out more than £15 million to 18 research teams to develop a new kind of medical technology: devices that can communicate directly with specific circuits in the human brain.

This is the biggest push the country has made into this area since the UK's Advanced Research and Invention Agency, known as ARIA, was set up in 2022. ARIA is a government body created to fund risky, cutting-edge research that might not happen otherwise.

University College London researchers received £8.1 million of that total, leading two of the 18 projects. Other major universities — King's College London, Imperial College London, and Cambridge — also got funding as part of a three-year partnership.

How the Money Is Being Spent

ARIA split the funding into three different types of work, each with its own budget and timeline.

The first type focuses on building the basic technology — the actual interfaces that could connect to the brain. This received £2 to 4 million.

The second type, which got the most money (£8 to 10 million), is about getting these technologies ready to test on real patients. This is closer to what you might eventually see in a hospital or clinic.

The third type, with £300,000, is for exploring new ideas that don't fit the other two categories.

All of these projects share one goal: create technologies that can talk to specific circuits in the brain — not just broad regions — to treat conditions like depression, dementia, chronic pain, and epilepsy. Most current treatments either use drugs that affect the whole body or target large areas of the brain. This approach is different.

At King's College London, researchers received funding to study gene therapy for psychiatric disorders. At Imperial College, a team is developing ultrasound techniques to deliver drugs through the blood-brain barrier, the body's protective filter that usually keeps large molecules out of the brain.

How Cambridge Fits In

Cambridge University is partnering with ARIA in a way that accelerates research moving from the lab into actual medical use. Rather than creating a separate research centre, ARIA is embedding itself within Cambridge's existing neuroscience teams — a practical model that borrows from how government agencies helped roll out the internet in the 1990s by working with universities and private companies instead of building everything from scratch.

What's Happening in the Rest of the World

The US started a similar effort over a decade ago. President Obama launched the BRAIN Initiative in 2013, backed by federal funding and private companies including Google and GlaxoSmithKline. That programme focused on mapping the brain's circuits and understanding how individual cells work together.

Private money is also flowing in. A foundation called the Weill Neurohub received a $106 million donation to connect three major American universities — UC San Francisco, UC Berkeley, and University of Washington — to work on epilepsy and Alzheimer's treatments. This built on an earlier $185 million gift to UC San Francisco in 2016 that created the Weill Institute for Neurosciences.

What This Could Change

The UK is betting on something specific: that targeting individual circuits in the brain, rather than using drugs that affect the whole body, could treat neurological diseases more effectively and with fewer side effects. Think of it like repairing a single broken wire in an enormous electrical system instead of replacing the whole power grid.

The challenge is real, though. For this to work, researchers need to figure out how to reliably pick up signals from deep in the brain, tell the difference between healthy and abnormal activity, and deliver a treatment without damaging surrounding tissue or interfering with normal brain function. These are hard problems that will probably take years to solve.

For Britain's research community, this funding marks the most serious, coordinated investment in brain technology the country has made in about 15 years. The structure — with multiple universities, a long timeframe, and partnerships between engineers, neuroscientists, and doctors — suggests ARIA is preparing for the kind of patient, collaborative work this field will need. If it works, it could position the UK as a leader in a type of medicine that the world is increasingly interested in.